Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2021-05-12 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2020年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2020 Annual General Meeting Resolution Announcement" for 奥锐特药业股份有限公司. It details the resolutions passed at the 2020 Annual General Meeting (AGM) held on May 12, 2021, including voting results on various agenda items such as the 2020 board work report, supervisory board report, financial statements, annual report, profit distribution plan, auditor appointment, and director/supervisor remuneration. The document includes attendance details, voting methods, and legal witness statements confirming the validity of the meeting and resolutions. The content is focused on announcing the official voting results and resolutions passed at the AGM rather than presenting the full annual report or financial statements themselves. The document length is 3210 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2021-05-12 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司2020年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2020 Annual General Meeting (AGM) of 奥锐特药业股份有限公司. It details the procedures of the AGM, attendance, voting methods (including network voting), and the results of the shareholder votes on various proposals such as the board report, financial report, profit distribution, and auditor appointment. The document focuses on the legality and validity of the AGM process and voting results rather than presenting financial data or the full annual report itself. It is not the annual report but a legal opinion on the AGM proceedings and voting outcomes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, supporting this classification with high confidence.
2021-05-12 Chinese
奥锐特药业股份有限公司2020年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2020 年年度股东大会会议资料" which translates to "2020 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda, meeting procedures, reports from the board and supervisory committee, financial results for 2020, and other materials typically presented at an AGM. The content includes multiple proposals for shareholder approval, reports on company performance, board changes, and audit reports, all structured as meeting materials for the 2020 AGM held in May 2021. The document length is about 15,000 characters, indicating it is the full meeting materials rather than a brief announcement or summary. Therefore, this document fits the category of AGM Information (AGM-R) as it is the presentation and materials shared during the Annual General Meeting.
2021-04-29 Chinese
奥锐特药业股份有限公司2021年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including total assets, net profit, cash flow, and shareholder information for the first quarter of 2021. The document explicitly states it is a quarterly report and includes financial statements and analysis for a period shorter than a full fiscal year. The length of the document (5131 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-28 Chinese
奥锐特药业股份有限公司第二届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of 奥锐特药业股份有限公司 regarding the resolutions passed at the fifth meeting of the second Supervisory Board. It includes approval of the company's 2021 first quarter report and an accounting policy change. The document references the full 2021 first quarter report being disclosed elsewhere (on stock exchange websites and newspapers), indicating this document is not the report itself but an announcement of the Supervisory Board's review and approval of that report. The document length is short (1268 characters) and mainly serves as a meeting resolution announcement rather than containing substantive financial data or the full report. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement of meeting resolutions and approvals, not the actual quarterly report (IR) or audit report (AR).
2021-04-28 Chinese
奥锐特药业股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy related to the adoption of a new lease accounting standard issued by the Ministry of Finance. It details the nature of the accounting policy change, its impact on the company, and the approval process by the board and independent directors. The document is relatively short (1961 characters) and does not contain financial statements or substantive financial data. It is not a full financial report but an announcement about a change in accounting policy. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.